Download Image
    
Share
  
Post
Pegipanermin for COVID-19
1 study with 77 patients
Hospital Icon Control
Hospital Icon Pegipanermin Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Pegipanermin studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -290% Mortality -290% Hospitalization -38% RCTs -290% Late -290% Favorspegipanermin Favorscontrol
Pegipanermin (XPro1595, INB03) is a biologic immunomodulator that uses dominant-negative TNF technology to selectively inhibit soluble tumor necrosis factor (sTNF) while sparing transmembrane TNF and its receptors.
Nov 18
2021
 Tesi et al., NCT04370236 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)
290% higher mortality (p=0.36), 241% higher ICU admission (p=0.15), 62% higher progression (p=0.4), and 38% longer hospitalization (p=0.16). RCT 79 hospitalized COVID-19 patients showing no significant differences with pegipanermin (INB03) treatment.